Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report

This case report highlights a patient who developed a rash resembling acute generalized exanthematous pustulosis (AGEP) after increasing her dose of semaglutide (Ozempic®), a GLP-1 agonist. The rash appeared outside the typical timeline for AGEP but matched its phenotypic and histopathologic characteristics. The report underscores the importance of considering a broad differential diagnosis for cutaneous eruptions and suggests that the reaction was likely due to the excipient propylene glycol, not semaglutide itself. It emphasizes the need for thorough ingredient analysis and multidisciplinary collaboration to ensure patient safety when using semaglutide.